drugset / Trial / NCT06875258
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
Phase 4
Recruiting
198 enrolled
The Netherlands Cancer Institute
Antoni van Leeuwenhoek Hospital · collabMemidis Pharma · collabViatris Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The PEHAB-II study is prospective, randomized trial designed to assess the effect of two different rehabilitation strategies on the recovery of erectile function in nerve sparing prostatectomy patients. The two rehabilitation strategies consist of 1)12 months daily doses of 100 mg Sildenafil combined with vacuum device (VED) therapy for 10 minutes a day, five times a week or 2) Standard of care: monotherapy with an on-demand dosage of 100mg Sildenafil. The study will be performed in multiple centers in the Netherlands.
Timeline
- Start
- 2024-01-15
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sildenafil | Unknown | 100 mg | — |
Indications
No indication recorded.